Budget Impact Analysis of The Use of Extended Half-Life Recombinant Factor VIII (EFMOROCTOG ALFA) For The Treatment of Congenital Haemophilia A- The Italian National Health System Perspective
Abstract
Authors
V Lorenzoni G Turchetti